title: Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies.
abstract: There have been no published studies evaluating the efficacy and safety of weekly liposomal amphotericin B as secondary prophylaxis in leukemic patients with invasive fungal infections (IFIs). We found in a retrospective review of our experience with 14 such patients admitted from 2003-2009 that the use of this approach was associated with frequent relapse of IFIs (36%) and kidney injury (36%).
authors: Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas Anderson Cancer Center, Houston, TX 77030, USA.
authors: Lizbeth
authors: L
authors: Cahuayme-Zuniga
authors: Russell E
authors: RE
authors: Lewis
authors: Victor E
authors: VE
authors: Mulanovich
authors: Dimitrios P
authors: DP
authors: Kontoyiannis
mesh_terms: D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D007938:Leukemia / Q000150:complications; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B